FASN and carcinoma: Because activation of fatty acid synthase (FASN), a key lipogenic enzyme catalyzing the terminal steps of de novo fatty acid (FA) biogenesis, is an early and near universal hallmark of most human carcinomas and their precursor lesions [19–25], we hypothesized that the correction of exacerbated endogenous lipogenesis might be sufficient to stably revert the malignant phenotype.